<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04454528</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 04119</org_study_id>
    <nct_id>NCT04454528</nct_id>
  </id_info>
  <brief_title>BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy</brief_title>
  <acronym>BreastVAX</acronym>
  <official_title>Preoperative Use of Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center at Penn Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center at Penn Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the feasibility of combining pembrolizumab with a&#xD;
      single fraction radiation boost in patients with early/ operable breast cancer. The secondary&#xD;
      objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and&#xD;
      histology exams, and to assess immune response on pre and post treatment blood and tissue&#xD;
      samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor&#xD;
      infiltrating lymphocytes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2 trial employing a Simon Two Stage design to evaluate the safety,&#xD;
      feasibility, and efficacy (defined as 10% increase in Ki67+ peripheral CD8 T cells&#xD;
      post-treatment) of a single pembrolizumab infusion with or without radiation boost prior to&#xD;
      definitive surgery in patients with operable breast cancer. The study has four arms. Arms 1&#xD;
      and 2 differ by the order of radiation boost and pembrolizumab administration. In arm 3,&#xD;
      patients will receive pembrolizumab alone. A minimum of 6 patients will be enrolled in the&#xD;
      safety run-in portion of the study. An additional 30 patients will be enrolled once&#xD;
      pembrolizumab with the combination radiation is considered feasible and additional funding is&#xD;
      available. Arm 4 represents our control arm in which patients will follow usual care but will&#xD;
      be consented for blood/tissue collection using a separate protocol (Penn IRB 801539).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of preoperative pembrolizumab administration combined with radiation boost in patients with operable breast cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Feasibility is defined as patient tolerability of the investigational treatment and no excessive delay in surgery in our participants. The interval to breast-conserving surgery and mastectomy was based on review of our records in patients undergoing breast cancer surgery in 2016. The average time to breast conservation surgery is 24.3 days (80% between 9 and 51 days) and for mastectomy with reconstruction 41.6 days (80% between 10 and 67 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess clinical response of treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate clinical response using the following assessments:&#xD;
clinical breast exam&#xD;
breast ultrasonography (US) imaging (optional) for tumor dimension changes.&#xD;
and histology (pathology) exams, Pathologic response is assess histologically on post-treatment tumor tissues. A major pathologic response will be defined as &lt;10% viable invasive tumor in treated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess immune response on pre- and post-treatment blood and tissue samples</measure>
    <time_frame>2 years</time_frame>
    <description>Assess immune response on pre- and post-treatment blood and tissue samples This study will track change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor infiltrating lymphocytes (TIL).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3 will receive pembrolizumab on day -14. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab infusion</intervention_name>
    <description>Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Checkpoint blockade administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood and tissue sampling</intervention_name>
    <description>Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Correlative studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All (male and female) participants must meet the following criteria during screening to be&#xD;
        enrolled in the study:&#xD;
&#xD;
          -  Is willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          -  Is ≥ 18 years of age on day of signing informed consent.&#xD;
&#xD;
          -  Have an ECOG Performance Status 0 - 1 at screening.&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
        Newly diagnosed clinical T1-2 N0-1 M0 breast cancer not eligible for I-SPY2 (to prevent&#xD;
        recruitment competition) or not undergoing neoadjuvant chemotherapy with at least one of&#xD;
        the following features:&#xD;
&#xD;
        Triple negative breast cancer defined using the ASCO CAP guidelines1 with the following&#xD;
        modification supported by a recent publication as ER ≤ 10%, PR ≤ 10%, and HER2(-)&#xD;
        determined by immunohistochemistry and/or fluorescence in situ hybridization analyses and&#xD;
        with tumor size ≤ 2.0 cm via breast ultrasound if deemed appropriate by the PI, any nodal&#xD;
        status, and not undergoing neoadjuvant chemotherapy.&#xD;
&#xD;
        Hormone receptor(+) HER2(-) (HR+ HER2[-]) breast caner with nodal involvement (node+&#xD;
        disease) confirmed on fine needle aspiration (FNA) or core needle biopsy and clinical T1 or&#xD;
        T2 tumor determined by breast ultrasound if deemed appropriate by the PI. FNA or core&#xD;
        needle biopsy of axilla node are standard diagnostic procedure to confirm nodal&#xD;
        involvement.&#xD;
&#xD;
        HR+ or HR- and HER2(+) breast cancer with clinical T1 tumor (tumor size ≤ 2 cm via breast&#xD;
        ultrasound if deemed appropriate by the PI), any nodal status, and not undergoing&#xD;
        neoadjuvant chemotherapy OR&#xD;
&#xD;
          -  Locally recurrent breast cancer with no prior radiation expecting surgical excision as&#xD;
             part of treatment • A female participant is eligible to participate if she is not&#xD;
             pregnant, not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 2 of the&#xD;
                  study protocol&#xD;
&#xD;
                  OR&#xD;
&#xD;
                  Locally recurrent breast cancer with no prior radiation expecting surgical&#xD;
                  excision as part of treatment.&#xD;
&#xD;
                    -  A female participant is eligible to participate if she is not pregnant (see&#xD;
                       Appendix 2), not breastfeeding, and at least one of the following conditions&#xD;
                       applies:&#xD;
&#xD;
                         1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 2&#xD;
                            OR&#xD;
&#xD;
                         2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 2&#xD;
                            during the treatment period and for at least 30 days (corresponding to&#xD;
                            time needed to eliminate the study drug pembrolizumab plus 30 days [a&#xD;
                            menstruation cycle] for study treatments with risk of genotoxicity)&#xD;
                            after the last dose of study treatment.&#xD;
&#xD;
                    -  Female participants of childbearing potential should be willing to use 2&#xD;
                       methods of birth control or be surgically sterile, or abstain from&#xD;
                       heterosexual activity for the course of the study through 120 days after the&#xD;
                       last dose of study medication Medically accepted methods of birth control&#xD;
                       include a diaphragm, cervical cap, latex condoms, surgical sterility,&#xD;
                       intrauterine devices (IUDs), hormonal implants, injectable contraceptives,&#xD;
                       or birth control pills. Participants of childbearing potential are those who&#xD;
                       have not been surgically sterilized or have not been free from menses for &gt;&#xD;
                       1 year.&#xD;
&#xD;
                    -  Ability to tolerate radiation therapy (e.g., lie flat and hold position).&#xD;
&#xD;
                    -  Demonstrate adequate hematologic, renal, hepatic, thyroid and bone marrow&#xD;
                       function. All screening labs should be performed within 21 days of treatment&#xD;
                       initiation. Adequate organ function defined as follows:&#xD;
&#xD;
                         1. ANC ≥1500/mcL&#xD;
&#xD;
                         2. Platelets ≥100,000 / mcL&#xD;
&#xD;
                         3. Hemoglobin ≥9g/dL&#xD;
&#xD;
                         4. Serum Creatinine ≤1.5 X upper limit of normal (ULN) OR ≥60 mL/ min for&#xD;
                            participant with creatinine levels &gt; 1.5 X institutional ULN Total&#xD;
&#xD;
                         5. Bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for participants with&#xD;
                            total bilirubin levels &gt; 1.5 ULN&#xD;
&#xD;
                         6. AST &amp; ALT ≤ 2.5 X ULN&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
                    -  1. A history of prior radiotherapy that precludes delivery of&#xD;
                       hypofractionated radiotherapy.&#xD;
&#xD;
                       2. Has received prior systemic anti-cancer therapy including investigational&#xD;
                       agents within 4 weeks [could consider shorter interval for kinase inhibitors&#xD;
                       or other short half-life drugs] prior to [randomization / allocation].&#xD;
&#xD;
                    -  Note: Participants must have recovered from all AEs due to previous&#xD;
                       therapies to ≤Grade 1 or baseline. Participants with&#xD;
&#xD;
                       ≤Grade 2 neuropathy may be eligible.&#xD;
&#xD;
                    -  Note: If participant received major surgery, they must have recovered&#xD;
                       adequately from the toxicity and/or complications from the intervention&#xD;
                       prior to starting study treatment.&#xD;
&#xD;
                       3. Has a known additional malignancy that is progressing or requires active&#xD;
                       treatment. Exceptions include basal cell carcinoma of the skin, squamous&#xD;
                       cell carcinoma of the skin, or in situ cervical cancer that has undergone&#xD;
                       potentially curative therapy.&#xD;
&#xD;
                       4. Has an active autoimmune disease requiring systemic treatment within the&#xD;
                       past 3 months or a documented history of clinically severe autoimmune&#xD;
                       disease, or a syndrome that requires systemic steroids or immunosuppressive&#xD;
                       agents. Subjects with vitiligo or resolved childhood asthma/atopy would be&#xD;
                       an exception to this rule. Subjects that require intermittent use of&#xD;
                       bronchodilators or local steroid injections would not be excluded from the&#xD;
                       study. Subjects with hypothyroidism stable on hormone replacement or&#xD;
                       Sjogren's syndrome will not be excluded from the study. Steroid prep due to&#xD;
                       dye allergies prior to staging scans or use in anti-emetic prophylaxis is&#xD;
                       allowed.&#xD;
&#xD;
                       5. Has evidence of interstitial lung disease or active, non-infectious&#xD;
                       pneumonitis or has as a history of (non-infectious) pneumonitis that&#xD;
                       required steroids or has current pneumonitis.&#xD;
&#xD;
                       6. Has an active infection requiring systemic therapy. 7. Has a history or&#xD;
                       current evidence of any condition, therapy, or laboratory abnormality that&#xD;
                       might confound the results of the trial, interfere with the subject's&#xD;
                       participation for the full duration of the trial, or is not in the best&#xD;
                       interest of the subject to participate, in the opinion of the treating&#xD;
                       investigator.&#xD;
&#xD;
                       8. Has known psychiatric or substance abuse disorders that would interfere&#xD;
                       with cooperation with the requirements of the trial.&#xD;
&#xD;
                       9. Is pregnant or breastfeeding or expecting to conceive or father children&#xD;
                       within the projected duration of the trial, starting with the pre-screening&#xD;
                       or screening visit through 120 days after the last dose of trial treatment.&#xD;
&#xD;
                       10. Has a known history of human immunodeficiency virus (HIV) (HIV 1/2&#xD;
                       antibodies).&#xD;
&#xD;
                       11. Has a known history of Hepatitis B (defined as Hepatitis B surface&#xD;
                       antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV&#xD;
                       RNA [qualitative] is detected) infection.&#xD;
&#xD;
                       - Note: no testing for Hepatitis B and Hepatitis C is required unless&#xD;
                       mandated by local health authority.&#xD;
&#xD;
                       12. Has received a live vaccine within 30 days prior to the first dose of&#xD;
                       trial treatment.&#xD;
&#xD;
                       13. History of allergy to pembrolizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia C Tchou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia C Tchou, MD</last_name>
    <phone>215-615-7575</phone>
    <email>Julia.tchou@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danielle R Jaffe, BS/BA</last_name>
    <phone>215-694-4399</phone>
    <email>Danielle.Jaffe@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Tchou, MD, PhD</last_name>
      <phone>800-789-7366</phone>
    </contact>
    <contact_backup>
      <last_name>Carolina Reyes, BS</last_name>
      <phone>6093153901</phone>
      <email>Carolina.Reyes1@Pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>September 19, 2022</last_update_submitted>
  <last_update_submitted_qc>September 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Abramson Cancer Center at Penn Medicine</investigator_affiliation>
    <investigator_full_name>Julia Tchou</investigator_full_name>
    <investigator_title>Professor of Clinical Surgery</investigator_title>
  </responsible_party>
  <keyword>Immune checkpoint blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04454528
org study id: UPCC 04119
nct id: NCT04454528
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
is us export: No
The primary objective is to determine the feasibility of combining pembrolizumab with a
      single fraction radiation boost in patients with early/ operable breast cancer. The secondary
      objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and
      histology exams, and to assess immune response on pre and post treatment blood and tissue
      samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor
      infiltrating lymphocytes
This is a Phase 1b/2 trial employing a Simon Two Stage design to evaluate the safety,
      feasibility, and efficacy (defined as 10% increase in Ki67+ peripheral CD8 T cells
      post-treatment) of a single pembrolizumab infusion with or without radiation boost prior to
      definitive surgery in patients with operable breast cancer. The study has four arms. Arms 1
      and 2 differ by the order of radiation boost and pembrolizumab administration. In arm 3,
      patients will receive pembrolizumab alone. A minimum of 6 patients will be enrolled in the
      safety run-in portion of the study. An additional 30 patients will be enrolled once
      pembrolizumab with the combination radiation is considered feasible and additional funding is
      available. Arm 4 represents our control arm in which patients will follow usual care but will
      be consented for blood/tissue collection using a separate protocol (Penn IRB 801539).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Feasibility of preoperative pembrolizumab administration combined with radiation boost in patients with operable breast cancer
time frame: 2 years
description: Feasibility is defined as patient tolerability of the investigational treatment and no excessive delay in surgery in our participants. The interval to breast-conserving surgery and mastectomy was based on review of our records in patients undergoing breast cancer surgery in 2016. The average time to breast conservation surgery is 24.3 days (80% between 9 and 51 days) and for mastectomy with reconstruction 41.6 days (80% between 10 and 67 days).
measure: Assess clinical response of treatment
time frame: 2 years
description: Evaluate clinical response using the following assessments:
clinical breast exam
breast ultrasonography (US) imaging (optional) for tumor dimension changes.
and histology (pathology) exams, Pathologic response is assess histologically on post-treatment tumor tissues. A major pathologic response will be defined as <10% viable invasive tumor in treated
measure: Assess immune response on pre- and post-treatment blood and tissue samples
time frame: 2 years
description: Assess immune response on pre- and post-treatment blood and tissue samples This study will track change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor infiltrating lymphocytes (TIL).
arm group label: Arm 1
arm group type: Active Comparator
description: Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
arm group label: Arm 2
arm group type: Active Comparator
description: Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
arm group label: Arm 3
arm group type: Active Comparator
description: Arm 3 will receive pembrolizumab on day -14. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
arm group label: Arm 4
arm group type: Other
description: Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
intervention type: Radiation
intervention name: Hypofractionated radiotherapy
description: Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
arm group label: Arm 1
arm group label: Arm 2
other name: Radiation therapy
intervention type: Drug
intervention name: Pembrolizumab infusion
description: Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
arm group label: Arm 1
arm group label: Arm 2
arm group label: Arm 3
other name: Checkpoint blockade administration
intervention type: Procedure
intervention name: Blood and tissue sampling
description: Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
arm group label: Arm 1
arm group label: Arm 2
arm group label: Arm 3
arm group label: Arm 4
other name: Correlative studies
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Julia C Tchou, MD
role: Principal Investigator
affiliation: University of Pennsylvania
last name: Julia C Tchou, MD
phone: 215-615-7575
email: Julia.tchou@pennmedicine.upenn.edu
last name: Danielle R Jaffe, BS/BA
phone: 215-694-4399
email: Danielle.Jaffe@pennmedicine.upenn.edu
facility: 
status: Recruiting
contact: 
contact backup: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: Abramson Cancer Center at Penn Medicine
investigator full name: Julia Tchou
investigator title: Professor of Clinical Surgery
mesh term: Breast Neoplasms
mesh term: Pembrolizumab
sharing ipd: No